Press releases

27 March, 2024

Regulatory

Abliva publishes prospectus in connection with rights issue covered to 100 per cent by subscription and guarantee undertakings and admission to trading of newly issued shares

The Board of Directors in Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has, in connection with the preferential rights issue announced on 22 February 2024, prepared a prospectus (the ...

8 June, 2022

Regulatory

Abliva publishes prospectus in connection with fully underwritten rights issue and admission to trading of newly issued shares

The Board of Directors in Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has, in connection with the new issues announced on 31 May, 2022, and the conversion of the Company's convertib ...

30 April, 202119 February, 2024

Regulatory

Abliva publishes prospectus and new information contained in the prospectus

Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or “the Company”), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, tod ...

24 April, 202019 February, 2024

Regulatory

Publication of supplementary prospectus related to NeuroVive’s rights issue

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has prepared a supplementary prospectus (the “Supplementary Prospectus”) to the prospectus that was approved and regi ...

3 April, 202019 February, 2024

Regulatory

NeuroVive publishes prospectus and new financial information included in the prospectus in connection with forthcoming rights issue

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has in connection with the forthcoming issue of shares with preferential rights for existing shareholders, announced ...

20 April, 2018

Regulatory

NeuroVive publishes supplementary prospectus

THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE THE DI ...

9 April, 2018

Regulatory

NeuroVive publishes prospectus in connection with preferential rights issue

THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF ...

14 April, 2016

Regulatory

NeuroVive publishes prospectus and announces new publication date of the Q1 interim report

On 28 February 2016, the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive") decided to carry out a new issue of shares and warrants (units) with preferential rights for the company ...

18 May, 2015

Regulatory

NeuroVive announces prospectus regarding admission to trading of new shares

The prospectus regarding the admission to trading of newly issued shares in NeuroVive Pharmaceutical AB (publ) is now available on the company's website www.neurovive.se and in the company's offices, ...

8 January, 2014

Regulatory

NeuroVive Pharmaceutical AB (publ) publishes prospectus

On 20 November 2013, the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive") decided to execute a rights issue. Coincident with this new share issue, NeuroVive has published a prosp ...